Thursday, 16 July 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 16 July 2026
News

Who owns the next blockbuster?

Posted 16 July 2026 AM

The current top-valued investigational drug candidates could rake in combined global sales of US$50 billion in 2032, if successfully launched.

The new list compiled by Evaluate ranks the leading 10 R&D programs by net present value (NPV) with more than half of the positions going to either oncology or gastrointestinal and endocrine candidates, reflecting “the quest for pan-cancer blockbusters” and “the obesity craze,” according to the data and analytics company.

To see the whole article, please login

Popular

Who's on the highest paid Aussie CEO list?
Aussie lands international role
Is the Pharma Rep dead? No way
Manufacturer and biotech team up
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (23)

Access & Reimbursement (1)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (4)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home